Commercial Stage Stocks
Revenue-generating life sciences and medical technology firms have transitioned from clinical development to the active scaling of proprietary therapies or diagnostic platforms. These entities navigate the complex transition from R&D centers to commercial organizations, where success depends on payer reimbursement approvals, physician adoption rates, and supply chain efficiency.
As of Oct 23, 2026, Commercial Stage has 185 US-listed companies worth $1.3T combined. The median member moved +0.3% over the past week; GALDY led among the 25 largest at +9.2% and IBRX trailed at -10.5%.
Companies in Commercial Stage
- NVS – Novartis AG ADR, $287B
- GILD – Gilead Sciences Inc, $193B
- PFE – Pfizer Inc, $171B
- REGN – Regeneron Pharmaceuticals Inc, $82.9B
- MRNA – Moderna Inc, $79.9B
- GALDY – GALDERMA GROUP AG, $54B
- TEVA – Teva Pharma Industries Ltd ADR, $46B
- ONC – BeiGene, Ltd., $43B
- ALNY – Alnylam Pharmaceuticals Inc, $30B
- VTRS – Viatris Inc, $21.2B
- EXEL – Exelixis Inc, $16.2B
- HALO – Halozyme Therapeutics Inc, $14.1B
- JAZZ – Jazz Pharmaceuticals PLC, $13.9B
- ELAN – Elanco Animal Health, $11.3B
- GKOS – Glaukos Corp, $10.4B
- MDGL – Madrigal Pharmaceuticals Inc, $10B
- KRYS – Krystal Biotech Inc, $9.6B
- IBRX – Immunitybio Inc, $8.8B
- TGTX – TG Therapeutics Inc, $8.1B
- AXSM – Axsome Therapeutics Inc, $7.6B
- ALKS – Alkermes Plc, $7.4B
- LNTH – Lantheus Holdings Inc, $6.5B
- IOVA – Iovance Biotherapeutics Inc, $6.4B
- RYTM – Rhythm Pharmaceuticals Inc, $6.3B
- LGND – Ligand Pharmaceuticals Incorporated, $6.1B
- GRAL – GRAIL, LLC, $5.7B
- MIRM – Mirum Pharmaceuticals Inc, $5.3B
- PTCT – PTC Therapeutics Inc, $5.3B
- GRFS – Grifols SA ADR, $5.2B
- BLLN – BillionToOne, Inc. Class A Common Stock, $4.8B
- INDV – Indivior PLC Ordinary Shares, $4.2B
- ARQT – Arcutis Biotherapeutics Inc, $4B
- ADPT – Adaptive Biotechnologies Corp, $3.9B
- VCYT – Veracyte Inc, $3.7B
- ERO – Ero Copper Corp, $3.6B
- TARS – Tarsus Pharmaceuticals Inc, $3.3B
- TMDX – TransMedics Group Inc, $2.5B
- ADMA – ADMA Biologics Inc, $2.4B
- PGEN – Precigen Inc, $2.3B
- AUPH – Aurinia Pharmaceuticals Inc, $2.2B
- AXGN – Axogen Inc, $2.2B
- HRMY – Harmony Biosciences Holdings, $2.1B
- VCEL – Vericel Corp Ord, $2.1B
- INSP – Inspire Medical Systems Inc, $2B
- XERS – Xeris Pharmaceuticals Inc, $2B
- BCRX – BioCryst Pharmaceuticals Inc, $2B
- ALMR – Alamar Biosciences, Inc. Common Stock, $2B
- LMAT – LeMaitre Vascular Inc, $2B
- ALVO – Alvotech, $1.9B
- NVAX – Novavax Inc, $1.9B
- ESTA – Establishment Labs Holdings Inc, $1.8B
- SRPT – Sarepta Therapeutics Inc, $1.8B
- NUVB – Nuvation Bio Inc, $1.7B
- PSNL – Personalis Inc, $1.7B
- KMTS – Kestra Medical Technologies, Ltd. Common Stock, $1.7B
- ANIP – ANI Pharmaceuticals Inc, $1.7B
- ETON – Eton Pharmaceuticals Inc, $1.6B
- ATEC – Alphatec Holdings Inc, $1.6B
- RARE – Ultragenyx, $1.6B
- MNKD – MannKind Corp, $1.2B
- OPK – Opko Health Inc, $1.2B
- SNDX – Syndax Pharmaceuticals Inc, $1.2B
- HROW – Harrow Health Inc, $1.1B
- TNDM – Tandem Diabetes Care Inc, $1.1B
- STAA – STAAR Surgical Company, $1.1B
- CSTL – Castle Biosciences Inc, $1.1B
- AORT – Artivion Inc, $1.1B
- BBNX – Beta Bionics, Inc. Common Stock, $1B
- PCRX – Pacira BioSciences, Inc., $1B
- PRCT – Procept Biorobotics Corp, $983M
- KURA – Kura Oncology Inc, $944M
- RIGL – Rigel Pharmaceuticals Inc, $881M
- ARDX – Ardelyx Inc, $842M
- SIBN – Si-Bone Inc, $810M
- VSTM – Verastem Inc, $781M
- GERN – Geron Corporation, $771M
- COLL – Collegium Pharmaceutical Inc, $701M
- PHAR – Pharming Group NV, $690M
- ZVRA – Zevra Therapeutics Inc., $676M
- MDXG – MiMedx Group Inc, $670M
- AQST – Aquestive Therapeutics Inc, $579M
- CRMD – CorMedix Inc, $576M
- PHAT – Phathom Pharmaceuticals Inc, $551M
- SSII – SS Innovations International Inc. Common Stock, $541M
- DCTH – Delcath Systems Inc, $534M
- VALN – Valneva SE ADR, $527M
- PBYI – Puma Biotechnology Inc, $506M
- TCMD – Tactile Systems Technology Inc, $501M
- MASS – 908 Devices Inc, $498M
- SENS – Senseonics Holdings, Inc. Common Stock, $484M
- BWAY – Brainsway Ltd, $474M
- EOLS – Evolus Inc, $472M
- SGHT – Sight Sciences Inc, $467M
- KMDA – Kamada, $466M
- CERS – Cerus Corporation, $459M
- NPCE – Neuropace Inc, $435M
- SPRY – ARS Pharmaceuticals, Inc, $427M
- RCEL – Avita Medical Ltd, $404M
- TRX – Tanzanian Royalty Exploration Corp, $393M
- SPCE – Virgin Galactic Holdings Inc, $391M
- SI – Shoulder Innovations, Inc., $390M
- EMBC – Embecta Corp, $389M
- CV – CapsoVision, Inc. Common Stock, $361M
- FENC – Fennec Pharmaceuticals Inc, $358M
- MOBI – Mobia Medical, Inc. Common Stock, $287M
- VNDA – Vanda Pharmaceuticals Inc, $273M
- AMRN – Amarin Corporation PLC, $261M
- ANIK – Anika Therapeutics Inc, $256M
- TMCI – Treace Medical Concepts Inc, $252M
- EVI – EVI Industries Inc, $246M
- QSI – QuantumSi Inc, $245M
- PROF – Profound Medical Corp, $242M
- UTMD – Utah Medical Products Inc, $237M
- SIGA – SIGA Technologies Inc, $234M
- ELMD – Electromed Inc, $231M
- RXST – Rxsight Inc, $203M
- XGN – Exagen Inc, $198M
- ACOG – Alpha Cognition Inc, $192M
- AKBA – Akebia Ther, $171M
- DERM – Journey Medical Corp, $160M
- CHRS – Coherus BioSciences Inc, $156M
- NYXH – Nyxoah, $121M
- LUCD – Lucid Diagnostics Inc, $116M
- CPIX – Cumberland Pharmaceuticals Inc, $111M
- CBUS – Cibus Global LLC, $108M
- IMDX – Insight Molecular Diagnostics Inc., $107M
- LENZ – LENZ Therapeutics Inc, $102M
- HYPR – Hyperfine Inc, $98.7M
- MIST – Milestone Pharmaceuticals Inc, $98.2M
- TNXP – Tonix Pharmaceuticals Holding Corp, $93.1M
- ECOR – Electrocore LLC, $87.6M
- NRXS – Neuraxis, Inc., $87M
- PTHS – Pelthos Therapeutics Inc., $85M
- CTOR – Citius Oncology, Inc., $81.2M
- SERA – Sera Prognostics Inc, $80.5M
- OM – Outset Medical Inc, $79.1M
- LUNG – Pulmonx Corp, $77.3M
- LNSR – LENSAR Inc, $77M
- VRCA – Verrica Pharmaceuticals Inc, $70.6M
- FBIO – Fortress Biotech Inc, $67.7M
- CITR – General Enterprise Ventures, Inc., $63.2M
- MDXH – MDxHealth SA, $63M
- DXR – Daxor Corporation, $58.9M
- HRTX – Heron Therapeuti, $58.1M
- COCH – Envoy Medical Inc., $50.9M
- MYO – Myomo Inc, $49.1M
- TELA – Tela Bio Inc, $47.4M
- SRTS – Sensus Healthcare Inc, $47.1M
- SNWV – SANUWAVE Health, Inc. Common Stock, $43.4M
- VHUB – VenHub Global, Inc., $36M
- CVRX – CVRx Inc, $36M
- RMTI – Rockwell Medical Inc, $31.6M
- OPTH – Optimi Health Corp. Common Shares, $23.6M
- BEAT – Heartbeam Inc, $22.6M
- NSPR – InspireMD Inc, $22.3M
- AYTU – Aytu BioScience Inc, $21.3M
- SCLX – Scilex Holding Company, $19.9M
- ARAY – Accuray Incorporated, $18.6M
- PAVM – PAVmed Inc, $18.3M
- PMI – Picard Medical, Inc., $17.2M
- AIFF – Firefly Neuroscience, Inc., $16M
- ICU – SeaStar Medical Holding Corporation, $15.3M
- CTXR – Citius Pharmaceuticals Inc, $14.6M
- FEMY – Femasys Inc, $13.1M
- CTSO – Cytosorbents Crp, $12.2M
- BFRI – Biofrontera Inc, $12M
- NMTC – Neuroone Medical Technologies Corp, $9.7M
- KPTI – Karyopharm Therapeutics Inc, $8.8M
- JAGX – Jaguar Animal Health Inc, $6.9M
- TNON – Tenon Medical Inc, $6.6M
- ACON – Aclarion Inc, $6.1M
- SONX – Sonendo Inc, $6.1M
- INBS – Intelligent Bio Solutions Inc., $5.2M
- ICCM – Icecure Medical, $4.9M
- SCNX – Scienture Holdings, Inc., $4.5M
- AIDX – 20/20 Biolabs, Inc. Common Stock, $3.3M
- EGRX – Eagle Pharmaceuticals Inc, $3.3M
- RDHL – Redhill Biopharma Ltd, $3M
- SXTP – 60 Degrees Pharmaceuticals, Inc. Common Stock, $3M
- ONCO – Onconetix Inc, $2.5M
- NUWE – Nuwellis Inc, $2M
- EVFM – Evofem Biosciences Inc, $980,722
- FEED – ENvue Medical Inc., $415,672
- TTOO – T2 Biosystms Inc, $19,631
- UTRS – Minerva Surgical Inc, $887